Should You Buy Medtronic plc Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Medtronic plc (MDT) is rated as a strong fundamental performer with a QOC score of 7.8/10. Trading at $93.75, our valuation engine evaluates whether the market price reflects the company's underlying earnings power.
The short answer: 2 of 11 CirclFi valuation models project upside for Medtronic plc (MDT) at $93.75 — the model consensus leans bearish, with a Quality Score of 7.8/10 and Value-Trap risk of 12/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Medtronic plc (MDT) in 2026?
What Is the Bull Case vs the Bear Case for Medtronic plc (MDT)?
| Bull case — $191.09 target (+103.8%) | Bear case — $34.25 target (-63.5%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Medtronic plc's score of 7.8/10 reflects durable competitive advantages that should sustain earnings power through market cycles. | According to the CirclFi Deep Alpha Valuation Engine, the Earnings Power Value (EPV) model sees the stock as overvalued with a fair value of $34.25 (-63.5%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $191.09 (+103.8%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +167.3% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: orphan drug designation could provide meaningful support for Medtronic plc's revenue and margin trajectory in the Medical Devices space. | Industry headwind: patent expiration revenue loss represents a meaningful risk for Medtronic plc and its Medical Devices peers. |
| The company's $119.9B market capitalization provides liquidity, stability, and the resource base to invest through downturns — structural advantages over smaller peers. |
How Does MDT Compare to Its Medical Devices Peers?
Valuation data pages: GEHC · BIO · INFU · TXG · LIVN · AXGN · CLPT · NNOX · LUDG · IRMD · PODD
Which Other Stocks Score Like MDT on Quality?
Closest companies to MDT’s Quality of Company score of 7.8/10, across all industries.
- SNEX — StoneX Group Inc. (QOC 7.8) · analysis
- RYN — Rayonier Inc. (QOC 7.8) · analysis
- SHO — Sunstone Hotel Investors, Inc. (QOC 7.8) · analysis
- JXN — Jackson Financial Inc. (QOC 7.8) · analysis
- BKU — BankUnited, Inc. (QOC 7.8) · analysis
- FIGR — Figure Technology Solutions, Inc. (QOC 7.8) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does MDT Appear In?
So Is Medtronic plc (MDT) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Medtronic plc at $93.75. 9/11 models flag overvaluation, median fair value sits at $56.87 (-39.3%), and the risk-reward profile appears unfavorable. Quality at 7.8/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Medtronic plc's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About MDT Stock?
Should I buy MDT stock right now?
Based on CirclFi's multi-model analysis, 2 of 11 models see upside for MDT at $93.75. The models are divided, which means the investment case depends heavily on your assumptions about Medtronic plc's future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Medtronic plc?
Key risks include: wide model disagreement (458% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does MDT compare to its competitors?
Among Medical Devices peers, MDT holds a Quality Score of 7.8/10. Comparable companies include GEHC (QOC 7.9), BIO (QOC 7.8), INFU (QOC 8.1). The relative ranking helps investors identify whether MDT offers better fundamental quality than alternatives in the same sector.
Is MDT a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. MDT's Quality Score of 7.8/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy MDT at?
CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $34.25 to $191.09. At $93.75, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for MDT.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad